ND-L02-s0201-005 Phase 2 randomized double blind placebo controlled study to evaluate safety, tolerability, biological activity, and PK of ND-L02-s0201 in subjects with IPF
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Nitto Denko Corporation
Start Date
August 24, 2018
End Date
December 31, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Nitto Denko Corporation
Start Date
August 24, 2018
End Date
December 31, 2023